The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial

Luo, Zhigang; Chen, Wei; Xiang, Ming; Wang, Hua; Xiao, Wei; Xu, Cheng; Li, Yunkui; Min, Jie; Tu, Qiang

doi:10.1016/j.eujim.2021.101305

Cited by 46 publications

(105 citation statements)

References 39 publications

(53 reference statements)

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…It was found that Xuebijing significantly suppressed IL-6, IL-8 and TNF-α ( p < 0.05). There was no significant difference in adverse events such as allergic shock ( Luo et al, 2021 ). In a prospective, randomized controlled study on 710 patients with community acquired pneumonitis, it was shown that Xuebijing significantly decreased the mortality rate on day 28 (15.87 vs 24.63%, p = 0.006), the time in need of mechanical ventilation (11 vs 16.5 days, p = 0.012), and duration of admission (12 vs 16 days, p = 0.004) than placebo, respectively.…”

Section: Herbal Products For Severe or Critical Covid-19 Patientsmentioning

confidence: 92%

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines

Ying¹,

Zhong²

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The outbreak of new coronavirus has tremendously threatened the public health system worldwide, including China. Chinese patent medicines (CPMs) have greatly contributed to the prevention and treatment of this viral infection, as well as the recovery of patients with COVID-19 infection. Therefore, numerous experts and guidelines recommend to take CPMs to treat pneumonia due to COVID-19.Aim of the Study: The present study reviewed CPMs recommended by the < Guidelines for diagnosis and management of COVID-19 (8th edition)> regarding evidence of their efficacy from clinical studies and the underlying mechanisms, which will lay the foundation for clinical use of these CPMs for COVID-19.Methods: The composition, efficacy, indications, history of use, and relevant clinical research on 14 recommended CPMs, including Huoxiangzhengqi capsules (pills, liquid, oral solution), Jinhuaqinggan granules, Lianhuaqingwen capsules (granules), Shufengjiedu capsules, Xiyanping injections, Xuebijing injections, Reduning injections, Tanreqing injections, Xingnaojing injections, Shenfu injections, Shengmai injections, Angongniuhuang pills, Suhexiang pills, were searched in both Chinese and English databases based on differences in stages of the disease and manifestations of such patients. Advantages of these CPMs over conventional treatments and their underlying mechanisms were explored by analyzing results from published articles and undergoing clinical trials.Results: Findings from clinical studies and Chinese experience in using these CPMs showed that CPMs, when used in combination with conventional treatments, were effective in managing COVID-19 with few side effects.Conclusion: CPMs have excellent efficacy in managing COVID-19 with a great potential for clinical use.

show abstract

Section: Herbal Products For Severe or Critical Covid-19 Patientsmentioning

confidence: 92%

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines

Ying¹,

Zhong²

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…At this stage, the mortality rate of patients is about 15% ( Godeau et al, 2021 ). XBJI is the only proprietary Chinese medicine approved in China for treating sepsis, and it significantly shortens the improvement time for major clinical symptoms and hospital stays ( Luo et al, 2021 ). The anti-inflammatory effect of XBJI arises from the regulation of the NF-κB signaling pathway ( Zhou et al, 2021 ).…”

Section: Research Status Of Antiviral Tcmsmentioning

confidence: 99%

Progress in Traditional Chinese Medicine Against Respiratory Viruses: A Review

Liu

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Respiratory viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV)-1, SARS-CoV-2, influenza A viruses, and respiratory syncytial virus, pose a serious threat to society. Based on the guiding principles of “holism” and “syndrome differentiation and treatment”, traditional Chinese medicine (TCM) has unique advantages in the treatment of respiratory virus diseases owing to the synergistic effect of multiple components and targets, which prevents drug resistance from arising. According to TCM theory, there are two main strategies in antiviral treatments, namely “dispelling evil” and “fu zheng”. Dispelling evil corresponds to the direct inhibition of virus growth and fu zheng corresponds to immune regulation, inflammation control, and tissue protection in the host. In this review, current progress in using TCMs against respiratory viruses is summarized according to modern biological theories. The prospects for developing TCMs against respiratory viruses is discussed to provide a reference for the research and development of innovative TCMs with multiple components, multiple targets, and low toxicity.

show abstract

“…In addition, XBJ has been shown to protect Vero E6 cells from SARS-CoV-2-induced cell death[ 81 ]. A randomized, double-blinded trial with 60 COVID-19 patients (3 dropped out) indicated that the secretion of IL-6, IL-8 and TNF-α was significantly suppressed in the routine medication plus XBJ therapy group [ 82 ]. After 14 days of treatment, the lymphocyte level was higher, and the C-reactive protein level was lower in the combination therapy group than the routine medication plus saline group [ 82 ].…”

Section: Treatment Of Covid-19 With Tcmmentioning

confidence: 99%

Current status of traditional Chinese medicine for the treatment of COVID-19 in China

et al. 2021

View full text Add to dashboard Cite

An ongoing outbreak of severe respiratory illness and pneumonia caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) commenced in December 2019, and the disease was named as coronavirus disease 2019 (COVID-19). Soon after, scientists identified the characteristics of SARS-CoV-2, including its genome sequence and protein structure. The clinical manifestations of COVID-19 have now been established; and nucleic acid amplification is used for the direct determination of the virus, whereas immunoassays can determine the antibodies against SARS-CoV-2. Clinical trials of several antiviral drugs are ongoing. However, there is still no specific drugs to treat COVID-19. Traditional Chinese medicine (TCM) was used in the treatment of COVID-19 during the early stages of the outbreak in China. Some ancient TCM prescriptions, which were efficacious in the treatment of severe acute respiratory syndrome (SARS) in 2002–03 and the influenza pandemic (H1N1) of 2009, have been improved by experienced TCM practitioners for the treatment of COVID-19 based on their clinical symptoms. These developed new prescriptions include Lianhua Qingwen capsules/granules, Jinhua Qinggan granules and XueBiJing injection, among others. In this review, we have summarized the presenting features of SARS-CoV-2, the clinical characteristics of COVID-19, and the progress in the treatment of COVID-19 using TCMs.

show abstract

The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial

Cited by 46 publications

References 39 publications

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines

Progress in Traditional Chinese Medicine Against Respiratory Viruses: A Review

Current status of traditional Chinese medicine for the treatment of COVID-19 in China

Contact Info

Product

Resources

About